Improved median Overall Survival and Progression Free Survival observed for Prophage-treated patients with Lower PD-L1 expression on peripheral blood monocytes at baseline LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ:AGEN), an immunology company developing innovative treatments for

LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), today announced additional details for the Company’s upcoming analyst and institutional investor meeting to be held on Thursday, May 14, 2015, from 4:30 to 6:30 PM Eastern Time in New York City.

Data simultaneously presented at ECCMID HZ/su vaccine achieves nearly 98% protection in people 70 or older This marks the second successful Phase 3 clinical program incorporating Agenus’ QS-21 Stimulon adjuvant LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc.

Final study results show significant reduction in malaria cases EMA currently reviewing the regulatory application LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immunology company developing innovative treatments for cancers and other diseases, announced today that final

Corporate Update Conference Call at 11 am ET Today Agenus to Host R&D Day in New York, NY on May 14 LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ:AGEN), an immunotherapy company developing immune-oncology checkpoint modulators (CPMs) and heat shock protein peptide-based vaccines as well

LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN) will release its first quarter 2015 financial results before the market opens on Thursday, April 23, 2015. Agenus executives will host a conference call at 11 a.m. Eastern Time the same day.

SECANT® yeast display technology to provide speed and cost advantages Combination with Agenus’ mammalian Retrocyte DisplayTM technology to result in a uniquely powerful antibody platform LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN) an immunology company developing innovative

Agenus to host conference call at 11 a.m. ET today LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ:AGEN), an immunology company developing novel therapeutic approaches based on checkpoint modulators (CPMs), heat shock protein-based vaccines, and immune adjuvants, today announced its

LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing a broad portfolio of checkpoint modulators (CPMs) and heat shock protein-based vaccines, as well as immune adjuvants, today announced that the Company will present at the Cowen and Company 35 th

LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), will release its fourth quarter and year end 2014 financial results before the market opens on Thursday, February 26, 2015. Agenus executives will host a conference call at 11 a.m. Eastern Time the same day.

LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immunology company developing a series of immune-oncology checkpoint modulators (CPMs), heat shock protein peptide-based vaccines, and immune adjuvants, today announced that the Company will present at the 17 th  Annual BIO CEO &

LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (Nasdaq: AGEN) will host a conference call today to discuss its global license, development and commercialization agreement with Incyte Corporation (Nasdaq: INCY) for novel immuno-oncology antibodies, which was announced earlier this morning.

Alliance to initially focus on four checkpoint modulator programs directed at GITR, OX40, TIM-3 and LAG-3 Incyte to have access to Agenus’ proprietary Retrocyte Display™ platform for the discovery of additional therapeutic antibodies Agenus to receive $60 million comprised of a $25 million

GSK’s ZOE-50 Phase 3 study meets primary endpoint of reducing the risk of shingles in people aged 50 and older Agenus is entitled to receive royalties on potential commercial sales of HZ/su LEXINGTON, Mass., Dec. 18, 2014 (GLOBE NEWSWIRE) -- Agenus Inc.

Agenus to host conference call beginning at 11 a.m. ET today LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a development pipeline of checkpoint modulators (CPMs), heat shock protein peptide-based vaccines, and adjuvants, today announced its

LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN) will report its third quarter 2014 financial results before the market opens on Friday, October 31, 2014. Agenus executives will host a conference call at 11 a.m. Eastern Time the same day. To access the live call, dial 416-640-5946.

LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing a portfolio of checkpoint modulators (CPMs), heat shock protein peptide-based vaccines, and adjuvants, today announced that Garo Armen, PhD, Chief Executive Officer, and Robert Stein, MD, PhD,

LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (Nasdaq:AGEN), an immuno-oncology company developing a portfolio of checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants, today announced that Robert Stein, MD, PhD, the company’s Chief Scientific Officer, will speak at Cambridge

Agenus to host conference call beginning at 11 a.m. ET today LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company developing a portfolio of checkpoint modulators (CPMs), heat shock protein peptide-based vaccines, and adjuvants, today announced its financial

GSK’s RTS,S is the world’s first malaria vaccine candidate to undergo regulatory review Agenus’ QS-21 Stimulon® is a component of RTS,S and in 16 additional vaccine candidates undergoing patient studies Submission triggered regulatory milestone payment; Agenus entitled to royalties on product sales

LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN) will release its second quarter 2014 financial results before the market opens on July 24, 2014. Agenus executives will host a conference call at 11:00 a.m. Eastern Time that same day. To access the live call, dial 719-325-2362.

Median Overall Survival Nearly Double than Expected with Standard of Care Alone LEXINGTON, Mass.--( BUSINESS WIRE )-- Agenus  Inc. (NASDAQ: AGEN), announced final results from a single-arm, multi-institutional, open-label, Phase 2 study showing that patients with newly diagnosed glioblastoma

Phase 2 trial in patients with genital herpes shows correlation between viral load reduction and CD8 T cell activation, an important clinical surrogate Trial shows booster shot demonstrates sustainable, long-term effect LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc.

LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (Nasdaq: AGEN), an immuno-oncology company developing a portfolio of checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants, today announced that Robert Stein, MD, PhD, the company’s Chief Scientific Officer, will present a company

LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus, Inc. (NASDAQ:AGEN), an immuno-oncology company developing a portfolio of checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants, announced that it has been selected for inclusion in the broad-market Russell 3000   Index and Russell